Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 4/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600235 | 0.86 | NMT1 (0.42) | NMT1CYP3A4TSHRTDP1AHR | |
| SCHEMBL7935640 | 0.80 | TDP1 (0.47) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL18302718 | 0.79 | GAA (0.32) | AHRKDM1AKDM1B | |
| SCHEMBL796033 | 0.79 | ALDH1A1 (0.41) | CYP3A4TSHRAHRKDM1AKDM1B | |
| SCHEMBL14956328 | 0.79 | NMT1 (0.38) | NMT1TDP1KDM1AKDM1B | |
| SCHEMBL30543313 | 0.79 | GAA (0.32) | AHRKDM1AKDM1B | |
| SCHEMBL8529116 | 0.76 | KDM1A (0.35) | AHRKDM1AKDM1B | |
| SCHEMBL13550057 | 0.75 | NMT1 (0.35) | NMT1 | |
| SCHEMBL16929987 | 0.75 | NMT1 (0.35) | NMT1CYP3A4TSHRTDP1GABRA1 | |
| SCHEMBL21225128 | 0.75 | GAA (0.38) | NMT1CYP3A4TSHRAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-10-24 | — | — | US | disclosed |
| EP-3404028-A1 | METHODS OF MAKING ANTIMICROBIAL COMPOUNDS | Melinta Therapeutics, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| US-9937183-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2697229-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20160220568-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2016-08-04 | — | — | US | disclosed |
| US-20160220568-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2016-08-04 | — | — | US | disclosed |
| US-20160214988-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2016-07-28 | — | — | US | disclosed |
| US-20160214988-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2016-07-28 | — | — | US | disclosed |
| US-9221827-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015035421-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035426-A1 | ANTIMICROBIAL COMPUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MELINTA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2697229-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Melinta Therapeutics, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012173689-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | NMT1 1319/4885CYP3A4 1470/4885TSHR 4385/4885 |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | NMT1 1319/4885CYP3A4 1470/4885TSHR 4385/4885 |
| US-20160214988-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | NMT1 1352/4885CYP3A4 1421/4885TSHR 4467/4885 |
| US-20160220568-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | GPX4, LPO, GPX1 | NMT1 3789/4885CYP3A4 1982/4885TSHR 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.